Trial Profile
An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Futuximab/modotuximab (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Symphogen
- 19 Jan 2019 Results establishing a popPK model for Sym004 using data from 4 trials (Sym004-01, Sym004-02, Sym004-05 and Sym004-06) presented at the 2019 Gastrointestinal Cancers Symposium
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2015 According to a Symphogen media release, data from this study were published in the Cancer Chemotherapy and Pharmacology Journal.